Stockscreener 앱 받기
24.73
0.86%
0.21
전일 마감가:
$24.52
열려 있는:
$24.57
하루 거래량:
28,127
Relative Volume:
0.33
시가총액:
$826.64M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+11.30%
1개월 성능:
-6.85%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$24.13
$25.29
1주일 범위
$20.36
$25.29
52주 변동 폭
$20.15
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
명칭
Spyglass Pharma Inc
전화
949-284-6904
주소
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
24.73 | 819.62M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | H.C. Wainwright | Buy |
| 2026-03-03 | 개시 | Citigroup | Buy |
| 2026-03-03 | 개시 | Jefferies | Buy |
| 2026-03-03 | 개시 | Leerink Partners | Outperform |
| 2026-03-03 | 개시 | Stifel | Buy |
Spyglass Pharma Inc 주식(SGP)의 최신 뉴스
All News for SGP : SpyGlass Pharma, Inc. - Zacks Investment Research
Dividend HistorySpyGlass Pharma, Inc. (SGP) - Zacks Investment Research
SpyGlass Pharma, Inc.: Fundamental Analysis and Financial Ratings | SGP | US85220G1094 - marketscreener.com
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SGP: SpyGlass Pharma, Inc.Insider Transations - Zacks Investment Research
SpyGlass Pharma, Inc. (SGP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SpyGlass Pharma Reports Fourth Quarter and Full-Year 2025 Results - VisionMonday.com
SpyGlass Pharma, Inc. (SGP) stock price, news, quote and history - Yahoo Finance UK
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target By Investing.com - Investing.com Canada
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target - Investing.com
SpyGlass Pharma’s BIM-IOL System: Transforming Glaucoma and Ocular Hypertension Treatment with Long-Acting Drug Delivery Solutions - Minichart
SpyGlass Pharma (NASDAQ: SGP) outlines long-acting glaucoma implant pipeline - Stock Titan
[8-K] SpyGlass Pharma, Inc. Reports Material Event - Stock Titan
97% stopped glaucoma drops in SpyGlass eye implant study - Stock Titan
New Glaucoma Treatment Uses Eye Implant for Three-Year Drug Delivery - CU Anschutz newsroom
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P TMI Index - marketscreener.com
SGP Stock Price, News & Analysis - Stock Titan
SpyGlass Valued at $900M After IPO - Orange County Business Journal
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating By Investing.com - Investing.com Canada
SpyGlass Pharma reports positive 12-month Phase 1/2 BIM-IOL results with high drop-free rates - TradingView
SpyGlass Pharma reports positive 12-month glaucoma device trial data - Investing.com Australia
SpyGlass Pharma reports positive 12-month glaucoma device trial data By Investing.com - Investing.com India
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System - The Manila Times
Spyglass Pharma surges on public debut; Agomab falls - MSN
Spyglass Pharma (NASDAQ:SGP) Upgraded at Zacks Research - Defense World
Polsinelli Advises SpyGlass Pharma on Intellectual Property Matters in Initial Public Offering - The National Law Review
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit - Bitget
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at Citigroup - Defense World
Latest SGP ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Stifel Initiates Coverage of SpyGlass Pharma (SGP) with Buy Recommendation - Nasdaq
Leerink initiates SpyGlass Pharma stock with Outperform rating By Investing.com - Investing.com Canada
Spyglass Pharma (NASDAQ:SGP) Now Covered by Stifel Nicolaus - MarketBeat
Jefferies initiates SpyGlass Pharma stock with buy rating on glaucoma drug - Investing.com Canada
Leerink Initiates SpyGlass Pharma at Outperform With $42 Price Target - marketscreener.com
Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target - marketscreener.com
Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential - Investing.com Canada
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tue - Benzinga
SGP SEC FilingsSpyGlass Pharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
SpyGlass Pharma (SGP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Spyglass Pharma (SGP) Stock Price, News & Analysis $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SGP News Today | Why did Spyglass Pharma stock go down today? $SGP - MarketBeat
Spyglass Pharma (SGP) Stock Trends and Sentiment 2026 $SGP - MarketBeat
Samsara Entities and Akkaraju Hold 6.3% of Spyglass Pharma (NASDAQ: SGP) - Stock Titan
Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders - AOL.com
New Enterprise Associates 17, L.P. Increases Stake in SpyGlass P - GuruFocus
NEA 17 (SGP) converts preferred and buys 937,500 SpyGlass Pharma shares - Stock Titan
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering - Legal Desire Media and Insights
Spyglass Pharma Inc (SGP) 재무 분석
Spyglass Pharma Inc (SGP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):